Market Place
Sourcing Support
All News #Library
Biotech
EMA Approves Safety Updates for Kite`s Yescarta, Tecartus
24 Apr 2026 //
FIRSTWORD PHARMA
Yescarta® Shows Consistent Benefits in R/R LBCL at ASH 2025
07 Dec 2025 //
BUSINESSWIRE
Kite Next-Gen Bicistronic CAR-T Shows Ph1 Promise in Lymphoma
06 Dec 2025 //
BUSINESSWIRE
Arcellx Reveals Positive Results In iMMagine-1 Study in Myeloma
06 Dec 2025 //
BUSINESSWIRE
Kite Puts $1.64B On Line For Pregene`s In Vivo CAR-T Deal
20 Oct 2025 //
FIERCE BIOTECH
Gilead, Kite To Revolutionize Cancer Care With ESMO 2025 Data
14 Oct 2025 //
INDPHARMAPOST
Kite Enters In Vivo CAR-T Space With $350M Interius Purchase
22 Aug 2025 //
BUSINESSWIRE
Gilead and Kite to Present Data at 2025 ASCO and EHA
15 May 2025 //
BUSINESSWIRE
Kite`s Yescarta® Highlights Curative Potential in Relapsed Lymphoma
08 Dec 2024 //
BUSINESSWIRE
Kite to Present CAR T-Cell Therapy Data at ASH 2024
05 Nov 2024 //
BUSINESSWIRE
Gilead`s Kite signs on with Cellares for cell therapy manufacturing test
27 Jun 2024 //
FIERCE PHARMA
Kite`s Tecartus Shows Sustained OS In Relapsed/Refractory ALL
03 Jun 2024 //
BUSINESSWIRE
Kite EHA 2024 Data Show CAR T-Cell Therapy Advances
14 May 2024 //
BUSINESSWIRE
U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy
21 Dec 2023 //
BUSINESSWIRE
Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023
11 Dec 2023 //
BUSINESSWIRE
Analyses of Kite’s Yescarta®CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas
11 Dec 2023 //
BUSINESSWIRE
Kite enlists Epic to apply epigenetic editing in creating next-gen CAR-T cells
31 Oct 2023 //
ENDPTS
Kite’s Car T-cell Therapy Yescarta Showes Durable Remission in ALYCANTE Study
18 Sep 2023 //
PRESS RELEASE
Kite’s Tecartus CAR T-cell Therapy Demonstrates 78% Complete Response Rate
06 Jun 2023 //
BUSINESSWIRE
KITE TO PRESENT NEW CAR T-CELL THERAPY DATA ACROSS MULTIPLE INDICATIONS
19 Apr 2023 //
PHARMIWEB
Kite`S Yescarta First Car T-Cell Therapy To Receive Health Canada Authorization
24 Mar 2023 //
NEWSWIRE
Kite’s Tecartus Demonstrates Overall Survival Benefit in Pivotal ZUMA-3 Trial
09 Feb 2023 //
BUSINESSWIRE
Kite And Arcellx Close Agreement To Co-Develop CART-DdBCMA In Multiple Myeloma
30 Jan 2023 //
PRESS RELEASE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.